Seven Fleet Capital Management LP Takes Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Seven Fleet Capital Management LP bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 110,000 shares of the company’s stock, valued at approximately $257,000.

Other institutional investors also recently modified their holdings of the company. Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $27,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Zentalis Pharmaceuticals during the first quarter valued at about $29,000. Qube Research & Technologies Ltd bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $37,000. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $41,000. Finally, State of Wyoming acquired a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter valued at about $67,000.

Zentalis Pharmaceuticals Stock Down 3.7%

ZNTL stock opened at $4.74 on Friday. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.21 and a twelve month high of $6.95. The stock’s 50 day moving average is $4.24 and its 200-day moving average is $3.55. The firm has a market capitalization of $337.44 million, a PE ratio of -2.74 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -1.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen raised Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Mizuho assumed coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective for the company. Guggenheim boosted their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Finally, Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.